keyword
https://read.qxmd.com/read/37811025/eosinophil-values-in-exacerbation-and-stable-chronic-obstructive-pulmonary-disease-and-its-relationship-to-maintenance-therapy-in-stable-chronic-obstructive-pulmonary-disease-patients
#21
JOURNAL ARTICLE
Muhammad Fachri, Mochammad Hatta, Fira Indah Lestari, Risky Akaputra, Fatimah Fatimah, Athariq Wahab, Yunita Arliniy, Ressy Dwiyanti, Ahmad Syukri, Ade Rifka Junita, Andini Febrianti, Muhammad Reza Primaguna, Azhar Azhar
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is characterised by persistent and progressive airflow limitations. The study aimed to determine the relationship between eosinophil values in patients with stable and exacerbated COPD, and the relationship of eosinophil values with two drug regimens used as maintenance therapy in stable COPD. MATERIALS AND METHODS: This cross-sectional study and the variables used in this study were eosinophil counts in stable and exacerbated COPD patients...
October 2023: Annals of Medicine and Surgery
https://read.qxmd.com/read/37803368/the-effect-of-inhaled-extrafine-beclometasone-dipropionate-formoterol-fumarate-glycopyrronium-bromide-on-distal-and-central-airway-indices-assessed-using-functional-respiratory-imaging-in-copd-darwiin
#22
JOURNAL ARTICLE
Gwen S Skloot, Alessandro Guasconi, Benjamin R Lavon, George Georges, Wilfried De Backer, Dmitry Galkin, Mauro Cortellini, Ilaria Panni, Jason H T Bates
BACKGROUND: This study, in patients with symptomatic chronic obstructive pulmonary disease (COPD), explored switching therapy from non-extrafine high-dose inhaled corticosteroid/long-acting β2 -agonist (ICS/LABA; fluticasone propionate/salmeterol [FP/SLM]) to extrafine medium-dose beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium (BDP/FF/G), both via dry-powder inhaler. Functional Respiratory Imaging, a quantitative computed tomography method with 3D reconstructions of pulmonary anatomy, was used to assess airway geometry and lung function...
October 6, 2023: Respiratory Research
https://read.qxmd.com/read/37800633/how-can-the-findings-of-the-emax-trial-on-long-acting-bronchodilation-in-chronic-obstructive-pulmonary-disease-be-applied-in-the-primary-care-setting
#23
REVIEW
Edward M Kerwin, Paul W Jones, Leif H Bjermer, François Maltais, Isabelle H Boucot, Ian P Naya, David A Lipson, Chris Compton, Lee Tombs, Claus F Vogelmeier
This review addresses outstanding questions regarding initial pharmacological management of chronic obstructive pulmonary disease (COPD). Optimizing initial treatment improves clinical outcomes in symptomatic patients, including those with low exacerbation risk. Long-acting muscarinic antagonist/long-acting β2 -agonist (LAMA/LABA) dual therapy improves lung function versus LAMA or LABA monotherapy, although other treatment benefits have been less consistently observed. The benefits of dual bronchodilation in symptomatic patients with COPD at low exacerbation risk, and its duration of efficacy and cost effectiveness in this population, are not yet fully established...
2023: Chronic Respiratory Disease
https://read.qxmd.com/read/37775734/comparative-cardiovascular-safety-of-laba-lama-fdc-versus-laba-ics-fdc-in-patients-with-chronic-obstructive-pulmonary-disease-a-population-based-cohort-study-with-a-target-trial-emulation-framework
#24
JOURNAL ARTICLE
Chun-Yu Chen, Sheng-Wei Pan, Chia-Chen Hsu, Jason J Liu, Hiraku Kumamaru, Yaa-Hui Dong
BACKGROUND: Use of combinations of long-acting β2 agonists/long-acting muscarinic antagonists (LABA/LAMA) in patients with chronic obstructive pulmonary disease (COPD) is increasing. Nevertheless, existing evidence on cardiovascular risk associated with LABA/LAMA versus another dual combination, LABA/inhaled corticosteroids (ICS), was limited and discrepant. AIM: The present cohort study aimed to examine comparative cardiovascular safety of LABA/LAMA and LABA/ICS with a target trial emulation framework, focusing on dual fixed-dose combination (FDC) therapies...
September 29, 2023: Respiratory Research
https://read.qxmd.com/read/37766800/guideline-discordant-inhaler-regimens-after-copd-hospitalization-associations-with-rurality-drive-time-to-care-and-fragmented-care-a-united-states-cohort-study
#25
JOURNAL ARTICLE
Arianne K Baldomero, Ken M Kunisaki, Chris H Wendt, Carrie Henning-Smith, Hildi J Hagedorn, Ann Bangerter, R Adams Dudley
BACKGROUND: Many patients receive guideline-discordant inhaler regimens after chronic obstructive pulmonary disease (COPD) hospitalization. Geography and fragmented care across multiple providers likely influence prescription of guideline-discordant inhaler regimens, but these have not been comprehensively studied. We assessed patient-level differences in guideline-discordant inhaler regimens by rurality, drive time to pulmonary specialty care, and fragmented care. METHODS: Retrospective cohort analysis using national Veterans Health Administration (VA) data among patients who received primary care and prescriptions from the VA...
October 2023: Lancet Reg Health Am
https://read.qxmd.com/read/37741092/management-goals-and-stable-phase-management-of-patients-with-chronic-obstructive-pulmonary-disease-in-the-japanese-respiratory-society-guideline-for-the-management-of-chronic-obstructive-pulmonary-disease-2022-6th-edition
#26
REVIEW
Yoko Shibata, Tomotaka Kawayama, Shigeo Muro, Hisatoshi Sugiura
Chronic obstructive pulmonary disease (COPD) is characterized by airflow obstruction on spirometry and symptoms such as dyspnea on exertion and chronic cough with sputum production, thus making it a significant healthcare issue worldwide. Japanese patients with COPD have unique characteristics compared to patients in Western countries, including older age and lower exacerbation frequency. The Japanese Respiratory Society (JRS) published the 6th edition of the COPD guideline in June 2022. This article introduces the management goals of COPD and describes its management during the stable phase, as outlined in the guideline...
September 20, 2023: Respiratory Investigation
https://read.qxmd.com/read/37725938/ocular-surface-intraocular-pressure-and-lens-condition-in-bronchodilator-and-steroid-treated-patients-with-chronic-pulmonary-disease
#27
JOURNAL ARTICLE
Özge Aydın Güçlü, Ayna Sariyeva Ismayilov
OBJECTIVES: The aim of this study was to investigate ocular surface, intraocular pressure and lens condition in bronchodilator- and steroid-treated chronic pulmonary disease patients. METHODS: In this cross-sectional clinical study, 101 patients with chronic pulmonary disease were treated with an inhaler and/or nebulized therapy for bronchodilatation. The patients were evaluated in 2 groups namely chronic obstructive pulmonary disease (COPD) and asthma. We investigated the effects of patient demographic characteristics, smoking, and medications on the presence of dry eye disease (DED), intraocular pressure, and cataract...
September 19, 2023: Medical Principles and Practice: International Journal of the Kuwait University, Health Science Centre
https://read.qxmd.com/read/37690008/2023-canadian-thoracic-society-guideline-on-pharmacotherapy-in-patients-with-stable-copd
#28
JOURNAL ARTICLE
Jean Bourbeau, Mohit Bhutani, Paul Hernandez, Shawn D Aaron, Marie-France Beauchesne, Sophie B Kermelly, Anthony D'Urzo, Avtar Lal, François Maltais, Jeffrey D Marciniuk, Sunita Mulpuru, Erika Penz, Don D Sin, Anne Van Dam, Joshua Wald, Brandie L Walker, Darcy D Marciniuk
Chronic obstructive pulmonary disease patient care must include confirming a diagnosis with postbronchodilator spirometry. Because of the clinical heterogeneity and the reality that airflow obstruction assessed by spirometry only partially reflects disease severity, a thorough clinical evaluation of the patient should include assessment of symptom burden and risk of exacerbations that permits the implementation of evidence-informed pharmacologic and nonpharmacologic interventions. This guideline provides recommendations from a comprehensive systematic review with a meta-analysis and expert-informed clinical remarks to optimize maintenance pharmacologic therapy for individuals with stable COPD, and a revised and practical treatment pathway based on new evidence since the 2019 update of the Canadian Thoracic Society (CTS) Guideline...
November 2023: Chest
https://read.qxmd.com/read/37599897/the-clinical-characteristics-and-outcomes-in-non-frequent-exacerbation-patients-with-chronic-obstructive-pulmonary-disease-in-the-chinese-population
#29
JOURNAL ARTICLE
Dan Liu, Qing Song, Yuqin Zeng, Rong Yi, Yi Liu, Xin Li, Yan Chen, Shan Cai, Ping Chen
BACKGROUND: We analyzed the clinical characteristics and outcomes in non-frequent exacerbation patients with chronic obstructive pulmonary disease (COPD). METHODS: In this retrospective cohort study, we enrolled patients with stable COPD from 12 hospitals. Non-frequent exacerbation was defined as less than two times of exacerbations in the past year. The non-frequent exacerbation patients were classified into less and more symptomatic groups based on the COPD Assessment Test (CAT) and modified Medical Research Council (mMRC)...
2023: International Journal of Chronic Obstructive Pulmonary Disease
https://read.qxmd.com/read/37592316/effect-of-fracture-risk-in-inhaled-corticosteroids-in-patients-with-chronic-obstructive-pulmonary-disease-a-systematic-review-and-meta-analysis
#30
JOURNAL ARTICLE
Shisheng Peng, Cong Tan, Lirong Du, Yanan Niu, Xiansheng Liu, Ruiying Wang
BACKGROUND: The fracture risk of patients with chronic obstructive pulmonary disease (COPD) treated with inhaled corticosteroids is controversial. And some large-scale randomized controlled trials have not solved this problem. The purpose of our systematic review and meta-analysis including 44 RCTs is to reveal the effect of inhaled corticosteroids on the fracture risk of COPD patients. METHODS: Two reviewers independently retrieved randomized controlled trials of inhaled corticosteroids or combinations of inhaled corticosteroids in the treatment of COPD from PubMed, Embase, Medline, Cochrane Library, and Web of Science...
August 17, 2023: BMC Pulmonary Medicine
https://read.qxmd.com/read/37583267/mortality-risk-reduction-with-budesonide-glycopyrrolate-formoterol-fumarate-versus-fluticasone-furoate-umeclidinium-vilanterol-in-copd-a-matching-adjusted-indirect-comparison-based-on-ethos-and-impact
#31
JOURNAL ARTICLE
Daiana Stolz, Erik Hermansson, Mario Ouwens, Barinder Singh, Akanksha Sharma, Dan Jackson, Patrick Darken, Jonathan Marshall, Karin Bowen, Hana Müllerová, Bernardino Alcázar Navarrete, Richard Russell, MeiLan K Han, Deniz Tansey-Dwyer
OBJECTIVE: Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide. While two approved fixed-dose inhaled corticosteroid/long-acting muscarinic antagonist (LAMA)/long-acting β2 -agonist (LABA) triple therapies reduce all-cause mortality (ACM) versus dual LAMA/LABA therapy in patients with COPD, head-to-head studies have not compared the effects of these therapies on ACM. We compared ACM in adults with moderate-to-very severe COPD receiving budesonide/glycopyrrolate/formoterol fumarate (BGF) in ETHOS versus fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) in IMPACT using a matching-adjusted indirect comparison (MAIC)...
August 15, 2023: Current Medical Research and Opinion
https://read.qxmd.com/read/37562659/evolving-to-a-single-inhaler-extrafine-laba-lama-ics-inhalation-technique-and-adherence-at-the-heart-of-copd-patient-care-trivolve
#32
JOURNAL ARTICLE
G Brusselle, U Himpe, P Fievez, M Leys, S Perez Bogerd, R Peché, E Vanderhelst, M Lins, P Capiau
OBJECTIVE: Incorrect inhaler use and poor treatment adherence have a negative impact on COPD outcomes. This multi-centre, single arm, non-interventional, phase IV study investigated whether inhalation technique, treatment adherence and patient outcomes change in patients who evolve from dual therapy or multiple inhaler triple therapy to single inhaler extrafine triple therapy (beclomethasone dipropionate (BDP, 87 μg), formoterol fumarate (FF, 5 μg) and glycopyrronium (G, 9 μg)) in combination with inhalation technique training...
August 8, 2023: Respiratory Medicine
https://read.qxmd.com/read/37524665/clinical-characteristics-and-economic-burden-of-asthma-in-china-a-multicenter-retrospective-study
#33
JOURNAL ARTICLE
Bin Shang, Xiangguo Li, Yu Xu, Wenxin Ren, Junren Wang, Chunyan Xing, Shujuan Jiang, Jian Sun
Asthma is a common chronic airway inflammation that produces a healthcare burden on the economy. We aim to obtain a better understanding of the clinical status and disease burden of patients with asthma in China. A retrospective study was carried out based on the computerized medical records in the Jinan Health Medical Big Data Platform between 2011 and 2019 (available data from 38 hospitals). The asthma severity of each patient was assessed retrospectively and categorized as mild, moderate, or severe according to Global Initiative for Asthma 2020 (GINA 2020)...
June 16, 2023: Iranian Journal of Allergy, Asthma, and Immunology
https://read.qxmd.com/read/37522870/classification-of-copd-as-abcd-according-to-gold-2011-and-2017-versions-in-copd-patients-at-university-medical-center-in-ho-chi-minh-city-vietnam
#34
JOURNAL ARTICLE
Vinh Nguyen-Nhu, Lam-Phuoc Nguyen, Sy Duong-Quy, Pham Le An, Tri Bui-Minh
In 2017, Global Initiative for Chronic Lung Disease (GOLD) made substantial changes to its ABCD group categorization. Although several studies had been conducted to assess the impact of the new GOLD category, there was no research on the change of the GOLD classification in Vietnam. This retrospective analysis was conducted at Asthma and COPD clinic at the University Medical Center in Ho Chi Minh City, Vietnam. Our study population comprised patients visiting Medical Center from January 2018 to January 2020...
July 28, 2023: Monaldi Archives for Chest Disease
https://read.qxmd.com/read/37521460/the-clinical-characteristics-and-treatment-response-of-patients-with-chronic-obstructive-pulmonary-disease-with-low-body-mass-index
#35
JOURNAL ARTICLE
Qing Song, Aiyuan Zhou, Ling Lin, Xueshan Li, Wei Cheng, Cong Liu, Yating Peng, Yuqin Zeng, Rong Yi, Yi Liu, Xin Li, Yan Chen, Shan Cai, Ping Chen
Background: This study aimed to analyze the clinical characteristics and treatment response of patients with chronic obstructive pulmonary disease (COPD) with low body mass index (BMI). Methods: In this cross-sectional study, we enrolled patients with stable COPD from the database setup by the Second Xiangya Hospital of Central South University. We classified the patients into three groups based on BMI: low-BMI (<18.5 kg/m2 ), normal-BMI (≥18.5 and <24.0 kg/m2 ), and high-BMI (≥24 kg/m2 ) groups...
2023: Frontiers in Pharmacology
https://read.qxmd.com/read/37521022/real-world-treatment-patterns-and-switching-following-moderate-severe-chronic-obstructive-pulmonary-disease-exacerbation-in-patients-with-commercial-or-medicare-insurance-in-the-united-states
#36
JOURNAL ARTICLE
Michael Bogart, Guillaume Germain, François Laliberté, Dominique Lejeune, Mei Sheng Duh
PURPOSE: There is limited literature regarding real-world treatment patterns of patients with COPD, particularly since the introduction of once-daily single-inhaler triple therapy with fluticasone furoate/umeclidinium/vilanterol in 2017. Here, we evaluated treatment patterns of patients with COPD before and after a COPD exacerbation. PATIENTS AND METHODS: Retrospective, descriptive study using medical and pharmacy claims data and enrollment information from the Optum® Clinformatics® Data Mart database...
2023: International Journal of Chronic Obstructive Pulmonary Disease
https://read.qxmd.com/read/37513942/asthma-and-copd-comparison-with-international-guidelines-and-medication-adherence-in-belgium
#37
JOURNAL ARTICLE
Natacha Biset, Mélanie Lelubre, Stéphanie Pochet, Carine De Vriese
Asthma and chronic obstructive pulmonary disease (COPD) are major chronic conditions. It is possible to limit their impact by controlling symptoms, which limits exacerbations and worsening of the disease, by choosing the appropriate treatment and ensuring that the patient adheres to it. The main purpose of this study was to assess medication adherence and persistence with inhaled medications for chronic treatment of asthma and COPD, as well as to evaluate the factors influencing this adherence. Medication adherence was measured from January 2013 to December 2016 using continuous multiple-interval measures of medication availability (CMA)...
July 20, 2023: Pharmaceuticals
https://read.qxmd.com/read/37507595/laba-lama-versus-laba-ics-fixed-dose-combinations-in-the-prevention-of-copd-exacerbations-a-modeling-analysis-of-literature-aggregate-data
#38
JOURNAL ARTICLE
Yiwen Gong, Zichao Sui, Yinghua Lv, Qingshan Zheng, Lujin Li
OBJECTIVES: This study aimed to quantitatively compare the efficacy and safety of long-acting β2 -agonist (LABA)/long-acting muscarinic antagonist (LAMA) and LABA/inhaled corticosteroid (ICS) fixed-dose combinations (FDCs) in preventing moderate or severe chronic obstructive pulmonary disease (COPD) exacerbations. METHODS: A literature search was performed using public databases. The time course characteristics of the probability of a moderate or severe exacerbation in stable COPD patients treated with LABA/LAMA and LABA/ICS FDCs were described by the parametric survival function...
July 29, 2023: European Journal of Clinical Pharmacology
https://read.qxmd.com/read/37434953/lack-of-clinical-control-in-copd-patients-depending-on-the-target-and-the-therapeutic-option
#39
MULTICENTER STUDY
Juan José Soler-Cataluña, Arturo Huerta, Pere Almagro, Diego González-Segura, Borja G Cosío
INTRODUCTION: According to the Global Initiative for chronic obstructive lung disease (GOLD), when a treatment is not achieving an appropriate response it should be switched taking into account the predominant treatable trait to target (dyspnea or exacerbations). The objective of the present study was to investigate the lack of clinical control according to the target and medication groups. MATERIALS AND METHODS: This was a post-hoc analysis of the CLAVE study, an observational, cross-sectional, multicenter study which evaluated the clinical control, and related-factors, in a cohort of 4801 patients with severe chronic obstructive pulmonary disease (COPD)...
2023: International Journal of Chronic Obstructive Pulmonary Disease
https://read.qxmd.com/read/37382864/delaying-disease-progression-in-copd-with-early-initiation-of-dual-bronchodilator-or-triple-inhaled-pharmacotherapy-depict-a-predictive-modelling-approach
#40
JOURNAL ARTICLE
Dave Singh, Diego Litewka, Rafael Páramo, Adrian Rendon, Abdullah Sayiner, Suzana E Tanni, Sudeep Acharya, Bhumika Aggarwal, Afisi S Ismaila, Raj Sharma, Peter Daley-Yates
INTRODUCTION: Clinical studies demonstrate an accelerated decline in lung function in patients with moderate chronic obstructive pulmonary disease (COPD) (Global Initiative for Chronic Obstructive Lung Disease [GOLD] grade 2) versus severe and very severe COPD (GOLD grades 3 and 4). This predictive modelling study assessed the impact of initiating pharmacotherapy earlier versus later on long-term disease progression in COPD. METHODS: The modelling approach used data on decline in forced expiratory volume in 1 s (FEV1 ) extracted from published studies to develop a longitudinal non-parametric superposition model of lung function decline with progressive impact of exacerbations from 0 per year to 3 per year and no ongoing pharmacotherapy...
June 29, 2023: Advances in Therapy
keyword
keyword
105611
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.